Literature DB >> 12900279

Vaccines for parasitic and bacterial diseases.

Steven G Reed1, Antonio Campos-Neto.   

Abstract

The first decade of the millennium should mark the beginning of a new era in vaccine development, reaping the rewards of advances in genome characterization, antigen identification, understanding the molecular bases of protective immune responses, and adjuvant design and development. Advances in all of these areas have culminated in vaccine candidates entering clinical testing. These include vaccines against two of humankind's oldest and deadliest diseases, tuberculosis and malaria. Several vaccine candidates for each of these diseases will be tested in humans during the next few years. A candidate vaccine for leishmaniasis, an infection that has taught us much about T-cell regulation of protection and disease in animal models, has been developed and is now in the clinic. There are indications both in animal models and in patients that vaccines may be used not only to protect but also to treat leishmania infections.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12900279     DOI: 10.1016/s0952-7915(03)00069-4

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  13 in total

1.  T-cell expression cloning of Porphyromonas gingivalis genes coding for T helper-biased immune responses during infection.

Authors:  Reginaldo B Gonçalves; Onir Leshem; Karen Bernards; John R Webb; Philip P Stashenko; Antonio Campos-Neto
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

2.  Mycobacterium hsp65 DNA entrapped into TDM-loaded PLGA microspheres induces protection in mice against Leishmania (Leishmania) major infection.

Authors:  Eduardo Antonio Ferraz Coelho; Carlos Alberto Pereira Tavares; Karla de Melo Lima; Célio Lopes Silva; José Maciel Rodrigues; Ana Paula Fernandes
Journal:  Parasitol Res       Date:  2006-01-24       Impact factor: 2.289

3.  Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis.

Authors:  Marie Breton; Michel J Tremblay; Marc Ouellette; Barbara Papadopoulou
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

4.  Skin test performed with highly purified Mycobacterium tuberculosis recombinant protein triggers tuberculin shock in infected guinea pigs.

Authors:  Stephen T Reece; Nicole Stride; Pamela Ovendale; Steven G Reed; Antonio Campos-Neto
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

5.  Three protein cocktails mediate delayed-type hypersensitivity responses indistinguishable from that elicited by purified protein derivative in the guinea pig model of Mycobacterium tuberculosis infection.

Authors:  Hongliang Yang; JoLynn Troudt; Ajay Grover; Kimberly Arnett; Megan Lucas; Yun Sang Cho; Helle Bielefeldt-Ohmann; Jennifer Taylor; Angelo Izzo; Karen M Dobos
Journal:  Infect Immun       Date:  2010-12-06       Impact factor: 3.441

6.  Th1 biased response to a novel Porphyromonas gingivalis protein aggravates bone resorption caused by this oral pathogen.

Authors:  Onir Leshem; Suely S Kashino; Reginaldo B Gonçalves; Noriyuki Suzuki; Masao Onodera; Akira Fujimura; Hajime Sasaki; Philip Stashenko; Antonio Campos-Neto
Journal:  Microbes Infect       Date:  2008-03-25       Impact factor: 2.700

7.  Guinea pig model of Mycobacterium tuberculosis latent/dormant infection.

Authors:  Suely S Kashino; Danielle R Napolitano; Ziedonis Skobe; Antonio Campos-Neto
Journal:  Microbes Infect       Date:  2008-09-06       Impact factor: 2.700

8.  Immunization with Leishmania major exogenous antigens protects susceptible BALB/c mice against challenge infection with L. major.

Authors:  Willy K Tonui; J Santiago Mejia; Lisa Hochberg; M Lamine Mbow; Jeffrey R Ryan; Adeline S T Chan; Samuel K Martin; Richard G Titus
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

9.  Optimized subunit vaccine protects against experimental leishmaniasis.

Authors:  Sylvie Bertholet; Yasuyuki Goto; Lauren Carter; Ajay Bhatia; Randall F Howard; Darrick Carter; Rhea N Coler; Thomas S Vedvick; Steven G Reed
Journal:  Vaccine       Date:  2009-09-26       Impact factor: 3.641

10.  Preventative and therapeutic vaccination to combat an experimental autoimmune kidney disease.

Authors:  Arpad Z Barabas; Chad D Cole; Arpad D Barabas; Rene Lafreniere
Journal:  Biologics       Date:  2007-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.